The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and ...

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

Regeneron Pharmaceuticals recently reported earnings for Q1 2025 with a revenue drop to $3,029 million compared to the prior year, though net income increased, reflecting robust profitability with ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other worst ...

We think investors are encouraged by the vagueness of the order and the significant room for negotiations. We sell different types of products and services to both investment professionals and ...

The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by Citigroup on May 14, 2025. The analyst firm set a price target for $700.00 expecting REGN to rise to within 12 ...

Another factor for clinicians to consider is that linvoseltamab and Tecvayli are given intravenously, while Elrexfio and ABBV-383 can be administered by subcutaneous injection. Regeneron’s ...

Regeneron’s gene therapy for otoferlin-related ... In the ongoing CHORD trial, children receive a single intracochlear injection of DB-OTO in one ear, with the other ear serving as a control.